Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers
Identifieur interne : 000606 ( Istex/Corpus ); précédent : 000605; suivant : 000607Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers
Auteurs : Françoise Muller ; Didier Thibaud ; Françoise Poloce ; Marie-Christine Gelineau ; Marguerite Bernard ; Christine Brochet ; Christine Millet ; Jean-Yves Réal ; Marc DommerguesSource :
- Prenatal Diagnosis [ 0197-3851 ] ; 2002-11.
English descriptors
Abstract
In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pd.449
Links to Exploration step
ISTEX:DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title><author><name sortKey="Muller, Francoise" sort="Muller, Francoise" uniqKey="Muller F" first="Françoise" last="Muller">Françoise Muller</name><affiliation><mods:affiliation>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Thibaud, Didier" sort="Thibaud, Didier" uniqKey="Thibaud D" first="Didier" last="Thibaud">Didier Thibaud</name><affiliation><mods:affiliation>Laboratoire Sery, Le Havre, France</mods:affiliation></affiliation></author><author><name sortKey="Poloce, Francoise" sort="Poloce, Francoise" uniqKey="Poloce F" first="Françoise" last="Poloce">Françoise Poloce</name><affiliation><mods:affiliation>Biologie, Hôtel Dieu, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Gelineau, Marie Hristine" sort="Gelineau, Marie Hristine" uniqKey="Gelineau M" first="Marie-Christine" last="Gelineau">Marie-Christine Gelineau</name><affiliation><mods:affiliation>Biologie, Hôtel Dieu, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Bernard, Marguerite" sort="Bernard, Marguerite" uniqKey="Bernard M" first="Marguerite" last="Bernard">Marguerite Bernard</name><affiliation><mods:affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Brochet, Christine" sort="Brochet, Christine" uniqKey="Brochet C" first="Christine" last="Brochet">Christine Brochet</name><affiliation><mods:affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Millet, Christine" sort="Millet, Christine" uniqKey="Millet C" first="Christine" last="Millet">Christine Millet</name><affiliation><mods:affiliation>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</mods:affiliation></affiliation></author><author><name sortKey="Real, Jean Ves" sort="Real, Jean Ves" uniqKey="Real J" first="Jean-Yves" last="Réal">Jean-Yves Réal</name><affiliation><mods:affiliation>Laboratoire Réal‐Carrié, Béziers, France</mods:affiliation></affiliation></author><author><name sortKey="Dommergues, Marc" sort="Dommergues, Marc" uniqKey="Dommergues M" first="Marc" last="Dommergues">Marc Dommergues</name><affiliation><mods:affiliation>Maternité, Hôpital Necker, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/pd.449</idno><idno type="url">https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000606</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title><author><name sortKey="Muller, Francoise" sort="Muller, Francoise" uniqKey="Muller F" first="Françoise" last="Muller">Françoise Muller</name><affiliation><mods:affiliation>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Thibaud, Didier" sort="Thibaud, Didier" uniqKey="Thibaud D" first="Didier" last="Thibaud">Didier Thibaud</name><affiliation><mods:affiliation>Laboratoire Sery, Le Havre, France</mods:affiliation></affiliation></author><author><name sortKey="Poloce, Francoise" sort="Poloce, Francoise" uniqKey="Poloce F" first="Françoise" last="Poloce">Françoise Poloce</name><affiliation><mods:affiliation>Biologie, Hôtel Dieu, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Gelineau, Marie Hristine" sort="Gelineau, Marie Hristine" uniqKey="Gelineau M" first="Marie-Christine" last="Gelineau">Marie-Christine Gelineau</name><affiliation><mods:affiliation>Biologie, Hôtel Dieu, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Bernard, Marguerite" sort="Bernard, Marguerite" uniqKey="Bernard M" first="Marguerite" last="Bernard">Marguerite Bernard</name><affiliation><mods:affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Brochet, Christine" sort="Brochet, Christine" uniqKey="Brochet C" first="Christine" last="Brochet">Christine Brochet</name><affiliation><mods:affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Millet, Christine" sort="Millet, Christine" uniqKey="Millet C" first="Christine" last="Millet">Christine Millet</name><affiliation><mods:affiliation>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</mods:affiliation></affiliation></author><author><name sortKey="Real, Jean Ves" sort="Real, Jean Ves" uniqKey="Real J" first="Jean-Yves" last="Réal">Jean-Yves Réal</name><affiliation><mods:affiliation>Laboratoire Réal‐Carrié, Béziers, France</mods:affiliation></affiliation></author><author><name sortKey="Dommergues, Marc" sort="Dommergues, Marc" uniqKey="Dommergues M" first="Marc" last="Dommergues">Marc Dommergues</name><affiliation><mods:affiliation>Maternité, Hôpital Necker, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Prenatal Diagnosis</title><title level="j" type="sub">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title level="j" type="abbrev">Prenat. Diagn.</title><idno type="ISSN">0197-3851</idno><idno type="eISSN">1097-0223</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1036">1036</biblScope><biblScope unit="page" to="1039">1039</biblScope></imprint><idno type="ISSN">0197-3851</idno></series><idno type="istex">DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6</idno><idno type="DOI">10.1002/pd.449</idno><idno type="ArticleID">PD449</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0197-3851</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>amniocentesis</term><term>fetal loss</term><term>premature birth</term><term>prenatal diagnosis</term><term>trisomy 21</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Françoise Muller</name><affiliations><json:string>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</json:string></affiliations></json:item><json:item><name>Didier Thibaud</name><affiliations><json:string>Laboratoire Sery, Le Havre, France</json:string></affiliations></json:item><json:item><name>Françoise Poloce</name><affiliations><json:string>Biologie, Hôtel Dieu, Lyon, France</json:string></affiliations></json:item><json:item><name>Marie‐Christine Gelineau</name><affiliations><json:string>Biologie, Hôtel Dieu, Lyon, France</json:string></affiliations></json:item><json:item><name>Marguerite Bernard</name><affiliations><json:string>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</json:string></affiliations></json:item><json:item><name>Christine Brochet</name><affiliations><json:string>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</json:string></affiliations></json:item><json:item><name>Christine Millet</name><affiliations><json:string>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</json:string></affiliations></json:item><json:item><name>Jean‐Yves Réal</name><affiliations><json:string>Laboratoire Réal‐Carrié, Béziers, France</json:string></affiliations></json:item><json:item><name>Marc Dommergues</name><affiliations><json:string>Maternité, Hôpital Necker, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>fetal loss</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prenatal diagnosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>trisomy 21</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>amniocentesis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>premature birth</value></json:item></subject><articleId><json:string>PD449</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.</abstract><qualityIndicators><score>4.966</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1294</abstractCharCount><pdfWordCount>2506</pdfWordCount><pdfCharCount>15601</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>205</abstractWordCount></qualityIndicators><title>Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>PD</json:string></publisherId><pages><total>4</total><last>1039</last><first>1036</first></pages><issn><json:string>0197-3851</json:string></issn><issue>11</issue><subject><json:item><value>Original Paper</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1097-0223</json:string></eissn><title>Prenatal Diagnosis</title><doi><json:string>10.1002/(ISSN)1097-0223</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/pd.449</json:string></doi><id>DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6</id><score>0.32613283</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><p>Copyright © 2002 John Wiley & Sons, Ltd.</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title><author xml:id="author-1"><persName><forename type="first">Françoise</forename><surname>Muller</surname></persName><note type="correspondence"><p>Correspondence: Biochimie, Hôpital Ambroise Paré, 92104 Boulogne, France.</p></note><affiliation>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Didier</forename><surname>Thibaud</surname></persName><affiliation>Laboratoire Sery, Le Havre, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Françoise</forename><surname>Poloce</surname></persName><affiliation>Biologie, Hôtel Dieu, Lyon, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Marie‐Christine</forename><surname>Gelineau</surname></persName><affiliation>Biologie, Hôtel Dieu, Lyon, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Marguerite</forename><surname>Bernard</surname></persName><affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Christine</forename><surname>Brochet</surname></persName><affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Christine</forename><surname>Millet</surname></persName><affiliation>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">Jean‐Yves</forename><surname>Réal</surname></persName><affiliation>Laboratoire Réal‐Carrié, Béziers, France</affiliation></author><author xml:id="author-9"><persName><forename type="first">Marc</forename><surname>Dommergues</surname></persName><affiliation>Maternité, Hôpital Necker, France</affiliation></author></analytic><monogr><title level="j">Prenatal Diagnosis</title><title level="j" type="sub">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title level="j" type="abbrev">Prenat. Diagn.</title><idno type="pISSN">0197-3851</idno><idno type="eISSN">1097-0223</idno><idno type="DOI">10.1002/(ISSN)1097-0223</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2002-11"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1036">1036</biblScope><biblScope unit="page" to="1039">1039</biblScope></imprint></monogr><idno type="istex">DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6</idno><idno type="DOI">10.1002/pd.449</idno><idno type="ArticleID">PD449</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>fetal loss</term></item><item><term>prenatal diagnosis</term></item><item><term>trisomy 21</term></item><item><term>amniocentesis</term></item><item><term>premature birth</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Original Paper</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2002-01-17">Received</change><change when="2002-06-30">Registration</change><change when="2002-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-0223</doi><issn type="print">0197-3851</issn><issn type="electronic">1097-0223</issn><idGroup><id type="product" value="PD"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PRENATAL DIAGNOSIS">Prenatal Diagnosis</title><title type="subtitle">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title type="short">Prenat. Diagn.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/pd.v22:11</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2002-11">November 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="17" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pd.449</doi><idGroup><id type="unit" value="PD449"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Original Paper</title><title type="tocHeading1">Original Papers</title></titleGroup><copyright ownership="publisher">Copyright © 2002 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="manuscriptReceived" date="2002-01-17"></event><event type="manuscriptRevised" date="2002-06-12"></event><event type="manuscriptAccepted" date="2002-06-30"></event><event type="firstOnline" date="2002-10-09"></event><event type="publishedOnlineFinalForm" date="2002-10-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">1036</numbering><numbering type="pageLast">1039</numbering></numberingGroup><correspondenceTo>Biochimie, Hôpital Ambroise Paré, 92104 Boulogne, France.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PD.PD449.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="22"></count></countGroup><titleGroup><title type="main" xml:lang="en">Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title><title type="short" xml:lang="en">RISK OF AMNIOCENTESIS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Françoise</givenNames><familyName>Muller</familyName></personName><contactDetails><email normalForm="francoise.muller@apr.ap-hop-paris.fr">francoise.muller@apr.ap‐hop‐paris.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Didier</givenNames><familyName>Thibaud</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Françoise</givenNames><familyName>Poloce</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Marie‐Christine</givenNames><familyName>Gelineau</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Marguerite</givenNames><familyName>Bernard</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Christine</givenNames><familyName>Brochet</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Christine</givenNames><familyName>Millet</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Jean‐Yves</givenNames><familyName>Réal</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Marc</givenNames><familyName>Dommergues</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire Sery, Le Havre, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Biologie, Hôtel Dieu, Lyon, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire Réal‐Carrié, Béziers, France</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="FR" type="organization"><unparsedAffiliation>Maternité, Hôpital Necker, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">fetal loss</keyword><keyword xml:id="kwd2">prenatal diagnosis</keyword><keyword xml:id="kwd3">trisomy 21</keyword><keyword xml:id="kwd4">amniocentesis</keyword><keyword xml:id="kwd5">premature birth</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>RISK OF AMNIOCENTESIS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers</title></titleInfo><name type="personal"><namePart type="given">Françoise</namePart><namePart type="family">Muller</namePart><affiliation>Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation><description>Correspondence: Biochimie, Hôpital Ambroise Paré, 92104 Boulogne, France.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Didier</namePart><namePart type="family">Thibaud</namePart><affiliation>Laboratoire Sery, Le Havre, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Françoise</namePart><namePart type="family">Poloce</namePart><affiliation>Biologie, Hôtel Dieu, Lyon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie‐Christine</namePart><namePart type="family">Gelineau</namePart><affiliation>Biologie, Hôtel Dieu, Lyon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marguerite</namePart><namePart type="family">Bernard</namePart><affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brochet</namePart><affiliation>Biochimie, Hôpital Pitié‐Salpétrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Millet</namePart><affiliation>Médecine Nucléaire, Centre Hospitalier, Poitiers, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Yves</namePart><namePart type="family">Réal</namePart><affiliation>Laboratoire Réal‐Carrié, Béziers, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Dommergues</namePart><affiliation>Maternité, Hôpital Necker, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2002-11</dateIssued><dateCaptured encoding="w3cdtf">2002-01-17</dateCaptured><dateValid encoding="w3cdtf">2002-06-30</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">22</extent></physicalDescription><abstract lang="en">In routine obstetrical practice, prior to offering invasive prenatal diagnosis, it is crucial to weigh the risks attendant on amniocentesis against the individual's risk of aneuploidy. We took advantage of a policy of follow‐up of patients undergoing Down syndrome maternal serum screening to compare the rates of fetal loss before 24 weeks and of early premature delivery at 24–28 weeks between women who underwent amniocentesis and women who did not. A total of 54 902 patients entered the study, of whom 4039 (7.35%) were lost to follow‐up and 387 were excluded because of a severe fetal abnormality. Of the 50 476 remaining patients, 3472 had an amniocentesis whereas 47 004 had not and served as controls. In the amniocentesis group, the fetal loss rate before 24 weeks was 1.12% (95% CI=1.08–1.15) and the 24–28 weeks premature delivery rate was 0.40% (95% CI=0.39–0.41) which was significantly higher than in controls (0.42% with 95% CI 0.41–0.43 and 0.24% with 95% CI 0.23–0.25, respectively). The 0.86% difference in adverse outcome rates between the amniocentesis and control groups may be attributable to amniocentesis and compares favourably with the positive predictive value of maternal serum markers (1.70%) observed in the present study. Copyright © 2002 John Wiley & Sons, Ltd.</abstract><subject lang="en"><genre>keywords</genre><topic>fetal loss</topic><topic>prenatal diagnosis</topic><topic>trisomy 21</topic><topic>amniocentesis</topic><topic>premature birth</topic></subject><relatedItem type="host"><titleInfo><title>Prenatal Diagnosis</title><subTitle>Published in Affiliation With the International Society for Prenatal Diagnosis</subTitle></titleInfo><titleInfo type="abbreviated"><title>Prenat. Diagn.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Original Paper</topic></subject><identifier type="ISSN">0197-3851</identifier><identifier type="eISSN">1097-0223</identifier><identifier type="DOI">10.1002/(ISSN)1097-0223</identifier><identifier type="PublisherID">PD</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1036</start><end>1039</end><total>4</total></extent></part></relatedItem><identifier type="istex">DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6</identifier><identifier type="DOI">10.1002/pd.449</identifier><identifier type="ArticleID">PD449</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Ltd.</recordOrigin></recordInfo></mods></metadata><enrichments><json:item><type>multicat</type><uri>https://api.istex.fr/document/DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6/enrichments/multicat</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000606 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000606 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DD4D69CC23D62FE61B1E91348CFAE75BBA70F7D6
|texte= Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers
}}
| This area was generated with Dilib version V0.6.25. |  |